Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

PPAR gamma activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats

Full text
Author(s):
Show less -
Festuccia, William T. [1] ; Blanchard, Pierre-Gilles [2] ; Belchior, Thiago [1] ; Chimin, Patricia [1] ; Paschoal, Vivian A. [1] ; Magdalon, Juliana [1] ; Hirabara, Sandro M. [1, 3] ; Simoes, Daniel [1] ; St-Pierre, Philippe [2] ; Carpinelli, Angelo [1] ; Marette, Andre [2] ; Deshaies, Yves [2]
Total Authors: 12
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo - Brazil
[2] Quebec Heart & Lung Inst Res Ctr, Fac Med, Dept Med, Quebec City, PQ G1V 4G5 - Canada
[3] Cruzeiro do Sul Univ, Inst Phys Act & Sports, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM; v. 306, n. 9, p. E1046-E1054, MAY 2014.
Web of Science Citations: 21
Abstract

mTOR inhibition with rapamycin induces a diabetes-like syndrome characterized by severe glucose intolerance, hyperinsulinemia, and hypertriglyceridemia, which is due to increased hepatic glucose production as well as reduced skeletal muscle glucose uptake and adipose tissue PPAR gamma activity. Herein, we tested the hypothesis that pharmacological PPAR gamma activation attenuates the diabetes-like syndrome associated with chronic mTOR inhibition. Rats treated with the mTOR inhibitor rapamycin (2 mg.kg(-1).day(-1)) in combination or not with the PPAR gamma ligand rosiglitazone (15 mg.kg(-1).day(-1)) for 15 days were evaluated for insulin secretion, glucose, insulin, and pyruvate tolerance, skeletal muscle and adipose tissue glucose uptake, and insulin signaling. Rosiglitazone corrected fasting hyperglycemia, attenuated the glucose and insulin intolerances, and abolished the increase in fasting plasma insulin and C-peptide levels induced by rapamycin. Surprisingly, rosiglitazone markedly increased the plasma insulin and C-peptide responses to refeeding in rapamycin-treated rats. Furthermore, rosiglitazone partially attenuated rapamycin-induced gluconeogenesis, as evidenced by the improved pyruvate tolerance and reduced mRNA levels of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Rosiglitazone also restored insulin's ability to stimulate glucose uptake and its incorporation into glycogen in skeletal muscle of rapamycin-treated rats, which was associated with normalization of Akt Ser(473) phosphorylation. However, the rapamycin-mediated impairments of adipose tissue glucose uptake and incorporation into triacylglycerol were unaffected by rosiglitazone. Our findings indicate that PPAR gamma activation ameliorates some of the disturbances in glucose homeostasis and insulin action associated with chronic rapamycin treatment by reducing gluconeogenesis and insulin secretion and restoring muscle insulin signaling and glucose uptake. (AU)

FAPESP's process: 09/15354-7 - Role of adipose tissue in the development of obesity and associated co-morbidities: investigation of molecular mechanism and search for alternative therapies
Grantee:William Tadeu Lara Festuccia
Support Opportunities: Research Grants - Young Investigators Grants